Ethris GmbH has entered into a collaboration with Diosynvax Ltd. to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses utilizing the company's highly differentiated mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilization platforms.